40774 Federal Register / Vol. 82, No. 165 / Monday, August 28, 2017 / Notices 

depending upon the availability of 

funds. The meetings may be conducted 

by teleconference or videoconference at 

the discretion of the Designated Federal 

Officer. The meetings shall be open to 

the public, except as determined 

otherwise by the Secretary, or other 

official to whom authority has been 

delegated, in accordance with the 

guidelines under Government in the 

Sunshine Act, 5 U.S.C. 552b(c). Notice 

of all meetings shall be provided to the 

public in accordance with the Federal 

Advisory Committee Act. Meetings shall 

be conducted and records of the 

proceedings shall be kept, as required 

by applicable laws and departmental 

policies. A quorum is required for the 

Task Force to meet to conduct business. 

A quorum shall consist of a majority of 

the Task Force’s members. When the 

Secretary or the Secretary’s designee 

determines that a meeting shall be 

closed or partially closed to the public, 

in accordance with provisions of 

Government in the Sunshine Act, 5 

U.S.C. 552b(c), then a report shall be 

prepared by the Designated Federal 

Officer that includes, at a minimum, a 

list of members and their business 

addresses, the Task Force’s functions, 

date and place of the meeting, and a 

summary of the Task Force’s activities 

and recommendations made during the 

fiscal year. A copy of the report shall be 

provided to the Department Committee 

Management Officer. 

Nominations: Nominations, including 

self-nominations, of individuals who 

have the specified expertise and 

knowledge will be considered for 

appointment as members of the Task 

Force. A nomination should include, at 

a minimum, the following for each 

nominee: (1) A letter of nomination that 

clearly states the name and affiliation of 

the nominee, the basis for the 

nomination, and a statement from the 

nominee that indicates that the 

individual is willing to serve as a 

member of the Task Force, if selected; 

(2) the nominator’s name, address, and 

daytime telephone number, and the 

address, telephone number, and email 

address of the individual being 

nominated; and (3) a current copy of the 

nominee’s curriculum vitae or resume, 

which should be limited to no more 

than 10 pages. 

Every effort will be made to ensure 

that the composition of the Task Force 

includes individuals from various 

geographic locations, including rural 

and underserved areas; racial and ethnic 

minorities; genders, and persons living 

with disabilities. 

Individuals other than officers or 

employees of the United States 

government being considered for 

appointment as members of the Task 

Force will be required to complete and 

submit a report of their financial 

holdings. An ethics review must be 

conducted to ensure that individuals 

appointed as members of the Task Force 

are not involved in any activity that may 

pose a potential conflict of interest for 

the official duties that are to be 

performed. This is a federal ethics 

requirement that must be satisfied upon 

entering the position and annually 

throughout the established term of 

appointment on the Task Force. 

Authority: Section 101 of the 

Comprehensive Addiction and Recovery 

Act of 2016 (Pub. L. 114–198) authorizes 

establishment of the Pain Management 

Best Practices Inter-Agency Task Force. 

The Task Force will be governed by 

provisions of the Federal Advisory 

Committee Act, Public Law 92–463, as 

amended (5 U.S.C. App. 2), which sets 

forth standards for the formation and 

use of Federal advisory committees. 

Dated: August 21, 2017. 

Donald Wright, 

Acting Assistant Secretary for Health. 

[FR Doc. 2017–18182 Filed 8–25–17; 8:45 am] 

BILLING CODE 4150–28–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

[Document Identifier: OS–0990–new] 

Agency Information Collection 

Request. 30-Day Public Comment 

Request 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: In compliance with the 

requirement of the Paperwork 

Reduction Act of 1995, the Office of the 

Secretary (OS), Department of Health 

and Human Services, is publishing the 

following summary of a proposed 

collection for public comment. 

DATES: Comments on the ICR must be 

received on or before September 27, 

2017. 

ADDRESSES: Submit your comments to 

OIRA_submission@omb.eop.gov or via 

facsimile to (202) 395–5806. 

FOR FURTHER INFORMATION CONTACT: 

Sherrette Funn, Sherrette.Funn@hhs.gov 

or (202) 795–7714. When submitting 

comments or requesting information, 

please include the document identifier 

0990-New-30D and project title for 

reference 

SUPPLEMENTARY INFORMATION: Interested 

persons are invited to send comments 

regarding this burden estimate or any 

other aspect of this collection of 

information, including any of the 

following subjects: (1) The necessity and 

utility of the proposed information 

collection for the proper performance of 

the agency’s functions; (2) the accuracy 

of the estimated burden; (3) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; and 

(4) the use of automated collection 

techniques or other forms of information 

technology to minimize the information 

collection burden. 

Project Title: Assessment of the 

Impact of Energy Development on the 

Behavioral Health of Women in Western 

North Dakota and Eastern Montana, The 

Region VIII Office of the Assistant 

Secretary for Health (OASH), Office on 

Women’s Health (OWH). 

Abstract: The Office on Women’s 

Health (OWH) in the Office of the 

Assistant Secretary for Health, U.S. 

Department of Health and Human 

Services (HHS) is requesting approval 

from the Office of Management and 

Budget (OMB) for a new data collection 

for the Assessment of the Impact of 

Energy Development on the Behavioral 

Health of Women in Western North 

Dakota and Eastern Montana. Its 

mission is to provide national 

leadership and coordination to improve 

the health of women and girls through 

policy, education and model programs. 

Region VIII OASH/OWH is interested in 

improving women’s behavioral health 

associated with the impact of energy 

development through gender based data 

collection and analysis. The discovery 

and subsequent development of the 

Parshall Oil Field within the Bakken 

region of Western North Dakota has led 

to significant economic opportunity and 

population growth in the region (Eastern 

Montana and Western North Dakota). 

Rapid population growth has many 

intended and unintended consequences, 

both positive and negative, on the social 

and economic environment of the region 

and, consequently, the population’s 

health and well-being. 

Need and Proposed Use of the 

Information: There are welldocumented environmental health 

issues associated with oil and gas 

development, including air, water, soil, 

noise, and light pollution. However, 

there are additional social, physical and 

mental health effects that are less well 

documented. Current research is very 

limited, but preliminary evidence 

suggests that women have unmet 

behavioral health needs due in part to 

the energy development and population 

surge in region. These data will 

ultimately be used to understand the 

impact of energy development on the 

behavioral health of women in Eastern 

Montana and Western North Dakota. 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 165 / Monday, August 28, 2017 / Notices 40775 

There will be a final report that is 

thematically organized and describes 

key findings and strategic 

recommendations for Region VIII 

OASH/OWH to consider supporting 

future evidence-based program 

development and implementation, 

policy recommendations, and future 

research. 

Likely Respondents: Data for this 

assessment will be collected through 

three mechanisms—a survey of women 

living in the assessment geography, 

focus groups with a cross-section of 

women and other key groups living in 

the assessment geography, key leaders 

and stakeholders across a variety of 

governmental and non-governmental 

sectors. 

The total annual burden hours 

estimated for this ICR are summarized 

in the table below. 

TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

Community Survey .......................................................................................... 500 1 15/60 125 

Focus Groups .................................................................................................. 240 1 90/60 360 

Interviews ......................................................................................................... 40 1 60/60 40 

Total .......................................................................................................... 780 1 40.4/60 525 

Terry S. Clark, 

Asst Information Collection Clearance 

Officer. 

[FR Doc. 2017–18117 Filed 8–25–17; 8:45 am] 

BILLING CODE 4150–33–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel NIAID Peer Review Meeting. 

Date: September 20–21, 2017. 

Time: 12:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 5601 

Fishers Lane, Rockville, MD 20892, 

(Telephone Conference Call). 

Contact Person: Kelly Y. Poe, Ph.D., 

Scientific Review Program, Division of 

Extramural Activities, Room 3F40B, National 

Institutes of Health, NIAID, 5601 Fishers 

Lane, MSC 9823, Bethesda, MD 20892–9823, 

(240) 669–5036, poeky@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: August 22, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–18121 Filed 8–25–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Chris Kornak, 240–627–3705, 

Chris.Kornak@nih.gov. Licensing 

information and copies of the U.S. 

patent applications listed below may be 

obtained by communicating with the 

indicated licensing contact at the 

Technology Transfer and Intellectual 

Property Office, National Institute of 

Allergy and Infectious Diseases, 5601 

Fishers Lane, Rockville, MD 20852; tel. 

301–496–2644. A signed Confidential 

Disclosure Agreement will be required 

to receive copies of unpublished patent 

applications. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

HIV Targets CD62L on Central Memory 

T Cells Through Viral Envelope 

Glycans for Adhesion and Induces 

Selectin Shedding for Viral Release 

Description of Technology 

Despite the success of anti-retroviral 

therapy in controlling HIV in infected 

individuals, treatment is less effective at 

eliminating HIV viral reservoirs. The 

nature of HIV reservoirs and the factors 

controlling their size and release are a 

major research focus for achieving a 

cure for HIV/AIDS. 

NIAID researchers have identified Lselectin/CD62L as a new target for 

treating HIV by inhibiting viral release 

from infected cells. They found that 

shedding of CD62L on T cells is 

required for the efficient release of HIV 

virus from infected cells. Further, they 

have shown that inhibition of CD62L 

shedding dramatically reduced HIV–1 

infection and viral release from both 

viremic and aviremic CD4+ T cells. 

Therefore, inhibitors for CD62L 

sheddase can function as an anti-HIV 

treatment that may be effective alone or 

in combination with existing 

therapeutics. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

• New target for HIV therapeutic 

development. 


asabaliauskas on DSKBBXCHB2PROD with NOTICES